Next Article in Journal
Metastasizing, Luciferase Transduced MAT‑Lu Rat Prostate Cancer Models: Follow up of Bolus and Metronomic Therapy with Doxorubicin as Model Drug
Next Article in Special Issue
Sputum-Based Molecular Biomarkers for the Early Detection of Lung Cancer: Limitations and Promise
Previous Article in Journal
Glioblastoma Stem-Like Cells—Biology and Therapeutic Implications
Previous Article in Special Issue
Tomato Lycopene and Lung Cancer Prevention: From Experimental to Human Studies
Cancers 2011, 3(2), 2667-2678; doi:10.3390/cancers3022667
Review

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

1
, 2
 and 3,*
Received: 28 April 2011; in revised form: 1 June 2011 / Accepted: 7 June 2011 / Published: 10 June 2011
(This article belongs to the Special Issue Lung Cancer)
View Full-Text   |   Download PDF [198 KB, uploaded 10 June 2011]
Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) cases comprise approximately 85% of the lung cancer cases. Before the era of target therapy, platinum-based doublet chemotherapy only led to a median survival of 8–9 months and a one-year survival of 30%–40% in patients with advanced NSCLC. In July 2002, gefitinib, a small-molecule epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), was approved for the treatment of patients with advanced NSCLC in Japan. After the widespread use of gefitinib in the treatment of NSCLC, there have been many new studies regarding the association between the clinical anticancer efficacy of gefitinib and the somatic EGFR mutation status in patients with NSCLC. This article summarizes the role of EGFR mutations in lung cancer and the use of EGFR antagonists in the treatment of lung cancer and its associated adverse effects.
Keywords: epidermal growth factor receptor; tyrosine kinase inhibitors; gefitinib; erlotinib epidermal growth factor receptor; tyrosine kinase inhibitors; gefitinib; erlotinib
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Chang, S.-C.; Chang, C.-Y.; Shih, J.-Y. The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers 2011, 3, 2667-2678.

AMA Style

Chang S-C, Chang C-Y, Shih J-Y. The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers. 2011; 3(2):2667-2678.

Chicago/Turabian Style

Chang, Shih-Chieh; Chang, Cheng-Yu; Shih, Jin-Yuan. 2011. "The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer." Cancers 3, no. 2: 2667-2678.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert